Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety - PubMed (original) (raw)

Clinical Trial

Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety

Justiniano Santos et al. J Hepatol. 2003 Aug.

Abstract

Background/aims: The most rational treatment of moderate ascites is spironolactone alone or in combination with furosemide. However, it is unknown which of these two treatment schedules is preferable.

Methods: One hundred nonazotemic cirrhotic patients with moderate ascites were randomly assigned to be treated with spironolactone and furosemide (Group 1: 50 patients) or with spironolactone alone (Group 2: 50 patients). If no response was obtained, the doses of diuretics were increased up to 400 mg/day of spironolactone and 160 mg/day of furosemide. In patients of group 2 not responding to 400 mg/day of spironolactone, furosemide was added. In cases with an excessive response, the dosage of diuretics was reduced.

Results: The response rate (98% in Group 1 vs. 94% in Group 2), the rapidity of ascites mobilization and the incidence of complications induced by diuretic therapy was similar in both groups. The need to reduce the diuretic dosage was significantly higher in Group 1 than Group 2 (68% vs. 34%; P=0.002).

Conclusions: In the treatment of moderate ascites, spironolactone alone seems to be as safe and effective as spironolactone associated with furosemide. Since spironolactone alone requires less dose adjustment, it would be more suitable for treating ascites on an outpatient basis.

PubMed Disclaimer

Cited by

Advances in the management of complications from cirrhosis.
Singh J, Ebaid M, Saab S. Singh J, et al. Gastroenterol Rep (Oxf). 2024 Aug 5;12:goae072. doi: 10.1093/gastro/goae072. eCollection 2024. Gastroenterol Rep (Oxf). 2024. PMID: 39104730 Free PMC article. Review.
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV).
Mandorfer M, Aigner E, Cejna M, Ferlitsch A, Datz C, Gräter T, Graziadei I, Gschwantler M, Hametner-Schreil S, Hofer H, Jachs M, Loizides A, Maieron A, Peck-Radosavljevic M, Rainer F, Scheiner B, Semmler G, Reider L, Reiter S, Schoder M, Schöfl R, Schwabl P, Stadlbauer V, Stauber R, Tatscher E, Trauner M, Ziachehabi A, Zoller H, Fickert P, Reiberger T. Mandorfer M, et al. Wien Klin Wochenschr. 2023 Sep;135(Suppl 3):493-523. doi: 10.1007/s00508-023-02229-w. Epub 2023 Jun 26. Wien Klin Wochenschr. 2023. PMID: 37358642 Free PMC article.
Asia-Pacific association for study of liver guidelines on management of ascites in liver disease.
Singh V, De A, Mehtani R, Angeli P, Maiwall R, Satapathy S, Singal AK, Saraya A, Sharma BC, Eapen CE, Rao PN, Shukla A, Shalimar, Choudhary NS, Alcantara-Payawal D, Arora V, Aithal G, Kulkarni A, Roy A, Shrestha A, Mamun Al Mahtab, Niriella MA, Siam TS, Zhang CQ, Huei LG, Yu ML, Roberts SK, Peng CY, Chen T, George J, Wong V, Yilmaz Y, Treeprasertsuk S, Kurniawan J, Kim SU, Younossi ZM, Sarin SK. Singh V, et al. Hepatol Int. 2023 Aug;17(4):792-826. doi: 10.1007/s12072-023-10536-7. Epub 2023 May 26. Hepatol Int. 2023. PMID: 37237088 No abstract available.
Urea Transporter Inhibitor 25a Reduces Ascites in Cirrhotic Rats.
Ying Y, Li N, Wang S, Zhang H, Zuo Y, Tang Y, Qiao P, Quan Y, Li M, Yang B. Ying Y, et al. Biomedicines. 2023 Feb 17;11(2):607. doi: 10.3390/biomedicines11020607. Biomedicines. 2023. PMID: 36831143 Free PMC article.
Hypertension: sex-related differences in drug treatment, prevalence and blood pressure control in primary care.
Bager JE, Manhem K, Andersson T, Hjerpe P, Bengtsson-Boström K, Ljungman C, Mourtzinis G. Bager JE, et al. J Hum Hypertens. 2023 Aug;37(8):662-670. doi: 10.1038/s41371-023-00801-5. Epub 2023 Jan 19. J Hum Hypertens. 2023. PMID: 36658330 Free PMC article. Review.

Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety - PubMed (original) (raw)